|By Marketwired .||
|September 3, 2014 07:30 AM EDT||
BOSTON, MA -- (Marketwired) -- 09/03/14 -- Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that J. Michael French, President and CEO, will present at the Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10, 2014 at the Palace Hotel in New York and at the Aegis Capital Corporation 2014 Healthcare and Technology Conference on Friday, September 12, 2014 at the Wynn Encore in Las Vegas.
The Company's presentation at the Rodman & Renshaw Conference is scheduled to begin at 12:05 PM ET and will be available via a live webcast. To access the webcast, please go to http://wsw.com/webcast/rrshq24/mrna.
There will be an opportunity for investors to meet one-on-one with management at both conferences. Interested investors should contact Ms. Lily Khaykina at [email protected] for the Rodman & Renshaw Conference and Ms. Mally Setton at [email protected] for the Aegis Capital Conference for conference details and admission. To learn more about the Rodman & Renshaw Conference and the Aegis Capital Conference, please visit http://www.rodm.com and http://www.aegiscapcorp.com/wp-content/uploads/2012/05/Vegas-2014-Flyer-12082014.pdf, respectively.
About Marina Biotech, Inc.
Marina Biotech is a leading nucleic acid-based drug discovery and development company focused on rare diseases. Our drug discovery platform, the broadest in the sector, allows us to develop compounds which best counter the underlying pathophysiology associated with a specific rare disease. Using this platform, we are developing proprietary single- and double-stranded nucleic acid therapeutics including siRNAs, microRNA mimics, antagomirs and antisense compounds intended to trigger various RNA-based mechanisms of action including RNA interference, microRNA replacement therapy, microRNA inhibition and mRNA translational inhibition, respectively. We believe our chemistry technologies and our comprehensive drug delivery technologies -- which utilize multiple, separate and distinct delivery modalities -- provide us with one of the most unique drug discovery engines for the development of nucleic acid-based therapeutics for rare and orphan diseases. Two of our delivery technologies are currently in human clinical trials, of which one -- SMARTICLES® -- is the only technology delivering both single-stranded and double-stranded nucleic acid payloads. Currently, we are advancing CEQ508, for which we have received FDA orphan drug designation, in a Phase 1 clinical program for patients with Familial Adenomatous Polyposis. In addition, we are expanding our rare disease focus to include myotonic dystrophy and Duchenne's muscular dystrophy. Our goal is to improve human health through the development of nucleic acid-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at www.marinabio.com.
Marina Biotech Forward-Looking Statements
Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent filings with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update or supplement forward-looking statements because of subsequent events.
In most cases, it is convenient to have some human interaction with a web (micro-)service, no matter how small it is. A traditional approach would be to create an HTTP interface, where user requests will be dispatched and HTML/CSS pages must be served. This approach is indeed very traditional for a web site, but not really convenient for a web service, which is not intended to be good looking, 24x7 up and running and UX-optimized. Instead, talking to a web service in a chat-bot mode would be muc...
Feb. 10, 2016 11:00 AM EST Reads: 251
It's easy to assume that your app will run on a fast and reliable network. The reality for your app's users, though, is often a slow, unreliable network with spotty coverage. What happens when the network doesn't work, or when the device is in airplane mode? You get unhappy, frustrated users. An offline-first app is an app that works, without error, when there is no network connection.
Feb. 10, 2016 11:00 AM EST Reads: 204
With an estimated 50 billion devices connected to the Internet by 2020, several industries will begin to expand their capabilities for retaining end point data at the edge to better utilize the range of data types and sheer volume of M2M data generated by the Internet of Things. In his session at @ThingsExpo, Don DeLoach, CEO and President of Infobright, will discuss the infrastructures businesses will need to implement to handle this explosion of data by providing specific use cases for filte...
Feb. 10, 2016 11:00 AM EST Reads: 179
More and more companies are looking to microservices as an architectural pattern for breaking apart applications into more manageable pieces so that agile teams can deliver new features quicker and more effectively. What this pattern has done more than anything to date is spark organizational transformations, setting the foundation for future application development. In practice, however, there are a number of considerations to make that go beyond simply “build, ship, and run,” which changes ho...
Feb. 10, 2016 10:45 AM EST Reads: 218
SYS-CON Events announced today that AppNeta, the leader in performance insight for business-critical web applications, will exhibit and present at SYS-CON's @DevOpsSummit at Cloud Expo New York, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. AppNeta is the only application performance monitoring (APM) company to provide solutions for all applications – applications you develop internally, business-critical SaaS applications you use and the networks that deli...
Feb. 10, 2016 10:45 AM EST Reads: 387
Fortunately, meaningful and tangible business cases for IoT are plentiful in a broad array of industries and vertical markets. These range from simple warranty cost reduction for capital intensive assets, to minimizing downtime for vital business tools, to creating feedback loops improving product design, to improving and enhancing enterprise customer experiences. All of these business cases, which will be briefly explored in this session, hinge on cost effectively extracting relevant data from ...
Feb. 10, 2016 10:45 AM EST
Cognitive Computing is becoming the foundation for a new generation of solutions that have the potential to transform business. Unlike traditional approaches to building solutions, a cognitive computing approach allows the data to help determine the way applications are designed. This contrasts with conventional software development that begins with defining logic based on the current way a business operates. In her session at 18th Cloud Expo, Judith S. Hurwitz, President and CEO of Hurwitz & ...
Feb. 10, 2016 10:45 AM EST Reads: 242
Feb. 10, 2016 10:30 AM EST Reads: 211
Feb. 10, 2016 10:04 AM EST
Feb. 10, 2016 09:30 AM EST Reads: 185
Feb. 10, 2016 09:30 AM EST
Feb. 10, 2016 09:20 AM EST
Feb. 10, 2016 09:00 AM EST Reads: 381
Feb. 10, 2016 09:00 AM EST Reads: 180
Feb. 10, 2016 08:00 AM EST